Abstract Number: 1752 • 2012 ACR/ARHP Annual Meeting
Depletion of CD4-Effector Memory T Cells and Clonally Expanded IgG4 Memory B Cells May Explain the Therapeutic Efficacy of Rituximab in IgG4-Related Disease: Studies Using Flow Cytometry and Single-Cell Sequencing
Depletion of CD4-effector memory T cells and clonally expanded IgG4 memory B cells may explain the therapeutic efficacy of rituximab in IgG4-related disease: Studies using…Abstract Number: 1753 • 2012 ACR/ARHP Annual Meeting
A Rheumatoid Factor Paradox: Inhibition of Rituximab-Induced Complement Dependent Cytotoxicity of B Cells
Background/Purpose: Rheumatoid factor (RF) is an autoantibody directed against the Fc portion of IgG antibodies. It is found in ~80% of patients with rheumatoid…Abstract Number: 1754 • 2012 ACR/ARHP Annual Meeting
Disruption of Dominant B-Cell and Plasma Cell Clones in Rheumatoid Arthritis Synovium by Rituximab Correlates with Treatment Response
Background/Purpose: Autoreactive B lymphocytes are thought to play an important role in rheumatoid arthritis (RA). B-cell depletion therapy by rituximab (RTX) has shown that targeting…Abstract Number: 1755 • 2012 ACR/ARHP Annual Meeting
The Alternative ΔCD20 Transcript Variant Is Not Expressed in B Cells and Synovial Tissue From Patients with Rheumatoid Arthritis
Background/Purpose: determining predictive factors for response to biologics may help to select appropriate treatment in patients with RA. Rituximab (RTX) is a chimeric monoclonal antibody…Abstract Number: 1756 • 2012 ACR/ARHP Annual Meeting
Peripheral Blood B Cell Subsets and BAFF/APRIL Receptor Expression, Together with Circulating BAFF and APRIL Levels, Are Disturbed in Rheumatoid Arthritis but Not in Ankylosing Spondylitis
Background/Purpose: B cells play a critical role in systemic autoimmune disease and especially rheumatoid arthritis (RA). BAFF and APRIL are involved in B cell activation…Abstract Number: 1757 • 2012 ACR/ARHP Annual Meeting
B Cell Activating Factor Receptor Expression After Rituximab: Comparison of Patients with Rheumatoid Arthritis and Thrombotic Thrombocytopenic Purpura
Background/Purpose: B cell depletion therapy based on rituximab (RTX) is an effective therapy for Rheumatoid Arthritis (RA) and for Thrombotic Thrombocytopenic Purpura (TTP). Serum B…Abstract Number: 1717 • 2012 ACR/ARHP Annual Meeting
Autologous Lipostructure in the Treatment of Fibrotic Perioral Changes in Systemic Sclerosis: A Pilot Study
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by varying degree of fibrosis in skin and other tissues. Therapeutic options for fibrotic changes are very…Abstract Number: 1718 • 2012 ACR/ARHP Annual Meeting
Cost Effectiveness of Nurse-Led Care for People with Rheumatoid Arthritis: A Multicentre RCT
Background/Purpose: Despite the establishment of the innovative rheumatology nurse-led clinics (NLC) in the UK, the evidence of their cost-effectiveness is unknown. This study aimed at…Abstract Number: 1719 • 2012 ACR/ARHP Annual Meeting
What Do Patients Put up with for the Benefit They Get From Methotrexate?
Background/Purpose: As with all effective drugs, Methotrexate (MTX) comes with a range of side effects. Some such as pneumonitis are severe enough to require the…Abstract Number: 1720 • 2012 ACR/ARHP Annual Meeting
Cardiovascular Risk Management in Rheumatoid Arthritis Is Nurse Led Intervention Effective?
Background/Purpose: There is a recognised increase in the incidence of heart disease in patients with rheumatoid arthritis (RA) Surveys of usual practice however frequently show…Abstract Number: 1721 • 2012 ACR/ARHP Annual Meeting
Development of User-Focused Standards of Care for Rheumatoid Arthritis the Www.Eumusc.Net Project – Work Package 5
Background/Purpose: The EUMUSC.net project facilitates cooperation between EU Member States and promotes a comprehensive European strategy to optimise musculoskeletal health.The purpose of Work package 5,…Abstract Number: 1722 • 2012 ACR/ARHP Annual Meeting
Exploring How Patients with Rheumatoid Arthritis Use a Methotrexate Decision Aid for Making Treatment Choices
Background/Purpose: For patients with rheumatoid arthritis (RA), making treatment decisions can be overwhelming. The literature describes a sense of ambivalence among patients with chronic diseases…Abstract Number: 1723 • 2012 ACR/ARHP Annual Meeting
The Development of the Rheumatoid Arthritis Patient Priorities in Pharmacological Intervention Outcome Measures
Background/Purpose: Previous research developed a set of 8 priority treatment outcomes generated by patients to complement the professionally developed ACR core set for RA. These…Abstract Number: 1724 • 2012 ACR/ARHP Annual Meeting
Pandemic Influenza Immunization in Primary Antiphospholipid Syndrome (PAPS): A Trigger to Autoantibody Production?
Background/Purpose: There are scarce data suggesting that pandemic influenza vaccination may induce antiphospholipid (APL) autoantibodies in inflammatory rheumatic diseases, particularly in systemic lupus erythematosus patients.…Abstract Number: 1725 • 2012 ACR/ARHP Annual Meeting
ANTI-Factor Xa Antibodies ARE Significantly Increased in Patients with Systemic LUPUS Erythematosus and Antiphospholipid Syndrome
Background/Purpose: Increased levels of antibodies against different serine proteases (SP) have been identified in patients with the Antiphospholipid Syndrome (APS) compared with healthy controls. These…
ACR Meeting Abstracts